MENU
+Compare
VIVS
Stock ticker: NASDAQ
AS OF
Dec 26, 04:59 PM (EDT)
Price
$2.01
Change
-$0.07 (-3.37%)
Capitalization
5.42M

VIVS VivoSim Lab Inc Forecast, Technical & Fundamental Analysis

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data... Show more

Industry: #Biotechnology
VIVS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for VIVS with price predictions
Dec 24, 2025

VIVS's RSI Oscillator ascends from oversold territory

The RSI Indicator for VIVS moved out of oversold territory on December 18, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In of the 42 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where VIVS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VIVS advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .

VIVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on VIVS as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for VIVS turned negative on December 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VIVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.768) is normal, around the industry mean (26.541). P/E Ratio (4.078) is within average values for comparable stocks, (51.479). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.873). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (30.581) is also within normal values, averaging (311.015).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
VIVS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a company which engages in developing and commercializing functional human tissues

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
N/A
Phone
N/A
Employees
N/A
Web
N/A
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CTM1.050.02
+1.94%
Castellum
REVB0.870.01
+1.15%
Revelation Biosciences Inc
BLMN6.540.03
+0.46%
Bloomin' Brands
HAFN5.31-0.01
-0.19%
Hafnia Limited
ZTO21.27-0.18
-0.84%
ZTO Express (Cayman)

VIVS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, VIVS has been loosely correlated with GLTO. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if VIVS jumps, then GLTO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VIVS
1D Price
Change %
VIVS100%
+7.22%
GLTO - VIVS
38%
Loosely correlated
+1.41%
ORMP - VIVS
37%
Loosely correlated
+6.78%
LVTX - VIVS
28%
Poorly correlated
N/A
ACET - VIVS
27%
Poorly correlated
+6.85%
KRRO - VIVS
26%
Poorly correlated
+0.12%
More